Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
OXFORD, United Kingdom, Sept. 05, 2016 -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the second quarter and half year ended 31 July 2016 on Thursday, 8 September 2016.
Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the half year results press release and a replay of the call will also be available through the Company's website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: +44 (0)1235 443 951 | |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP | ||
| (Nominated Adviser) | ||
| Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7148 7900 | |
| N+1 Singer | ||
| (Broker) | ||
| Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 | |
| MacDougall Biomedical Communications | ||
| (US media contact) | Tel: +1 781 235 3060 | |
| Chris Erdman / Karen Sharma | [email protected] / | |
| [email protected] | ||
| Consilium Strategic Communications | ||
| (Financial public relations, UK) | Tel: +44 (0)20 3709 5700 | |
| Mary-Jane Elliott / Sue Stuart / | [email protected] | |
| Jessica Hodgson / Lindsey Neville |
